These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17957927)

  • 1. The prognostic value of p53 immunostaining in node-negative breast carcinoma.
    Soontrapornchai P; Chanvitan A; Koontongkaew S; Sunpaweravong S
    J Med Assoc Thai; 2007 Sep; 90(9):1833-8. PubMed ID: 17957927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer.
    Iacopetta B; Grieu F; Powell B; Soong R; McCaul K; Seshadri R
    Clin Cancer Res; 1998 Jul; 4(7):1597-602. PubMed ID: 9676832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients.
    Falette N; Paperin MP; Treilleux I; Gratadour AC; Peloux N; Mignotte H; Tooke N; Löfman E; Inganäs M; Bremond A; Ozturk M; Puisieux A
    Cancer Res; 1998 Apr; 58(7):1451-5. PubMed ID: 9537247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
    Shao ZM; Wu J; Shen ZZ; Nguyen M
    Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
    Domagala W; Markiewski M; Harezga B; Dukowicz A; Osborn M
    Clin Cancer Res; 1996 Jan; 2(1):147-54. PubMed ID: 9816101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 as a specific prognostic factor in triple-negative breast cancer.
    Chae BJ; Bae JS; Lee A; Park WC; Seo YJ; Song BJ; Kim JS; Jung SS
    Jpn J Clin Oncol; 2009 Apr; 39(4):217-24. PubMed ID: 19304743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
    Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of p53 in node negative breast cancer.
    Kristen P; Müller JG; Caffier H
    Anticancer Res; 1997; 17(4B):2869-71. PubMed ID: 9329550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
    Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
    Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
    Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Peripheral blood mutated p53 DNA and its clinical value in human breast cancer].
    Di GH; Liu G; Wu J; Shen ZZ; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2003 Mar; 25(2):137-40. PubMed ID: 12795838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
    Di Saverio S; Gutierrez J; Avisar E
    Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast.
    Kourea HP; Koutras AK; Zolota V; Grimani I; Tzoracoeleftherakis E; Koukouras D; Fountzilas G; Gogas H; Kyriakou K; Adamou A; Kalofonos HP
    Anticancer Res; 2006; 26(2B):1657-68. PubMed ID: 16619588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 expression as a prognostic marker in inflammatory breast cancer.
    Gonzalez-Angulo AM; Sneige N; Buzdar AU; Valero V; Kau SW; Broglio K; Yamamura Y; Hortobagyi GN; Cristofanilli M
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6215-21. PubMed ID: 15448010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer.
    Lindahl T; Landberg G; Ahlgren J; Nordgren H; Norberg T; Klaar S; Holmberg L; Bergh J
    Carcinogenesis; 2004 Mar; 25(3):375-80. PubMed ID: 14633656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic variables in male breast cancer.
    Clark JL; Nguyen PL; Jaszcz WB; Jatoi A; Niehans GA
    Am Surg; 2000 May; 66(5):502-11. PubMed ID: 10824754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.